ELISA analysis of more than 120 plasma samples from non-cancer and cancer patients with HER2+ breast cancer revealed WFIKKN2 to have sensitivity and specificity of up to 89% and 60%, respectively. This evidence concerns the gene ERBB2 and breast carcinoma.